SRR975558
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- INTERFERON_GAMMA_RESPONSE+0.370
- ALLOGRAFT_REJECTION+0.330
- INFLAMMATORY_RESPONSE+0.320
- TGF_BETA_SIGNALING+0.310
- PANCREAS_BETA_CELLS+0.300
- APICAL_JUNCTION+0.290
- KRAS_SIGNALING_DN+0.260
- APICAL_SURFACE+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.630
- MYC_TARGETS_V1-0.590
- OXIDATIVE_PHOSPHORYLATION-0.560
- E2F_TARGETS-0.470
- FATTY_ACID_METABOLISM-0.440
- MTORC1_SIGNALING-0.440
- UNFOLDED_PROTEIN_RESPONSE-0.430
- G2M_CHECKPOINT-0.380
- XENOBIOTIC_METABOLISM-0.380
- BILE_ACID_METABOLISM-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.875 |
| 2 | 44eb0b78-9761-4131-b831-85e765a24e6b | — | — | 0.868 |
| 3 | 767fc312-2c66-43f7-b78e-bf79e03e3a0a | — | — | 0.855 |
| 4 | EPT0561 | EPN | Supratentorial EPN | 0.855 |
| 5 | 2cec663c-00c8-48b5-967b-f2a53c0fb409 | — | — | 0.850 |
| 6 | 86db93b2-14b0-4094-bd69-222582df130c | — | — | 0.849 |
| 7 | C3N-03233 | — | cohortA1 | 0.847 |
| 8 | TCGA-55-7227-01A-11R-2039-07 | — | cohortA1 | 0.844 |
| 9 | TCGA-93-A4JQ-01A-11R-A24X-07 | — | cohortA1 | 0.844 |
| 10 | AUR-AG12-TTP1-A-1-0-R-A741-41 | — | A | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |